Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005592 · ClinicalTrials.gov registry record · Phase 2
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00005592 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 23 participants.
The verdict
NCT00005592, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radiation to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of rituximab and ibritumomab tiuxetan in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
Interventions
- BIOLOGICAL rituximab
- RADIATION indium In 111 ibritumomab tiuxetan
- BIOLOGICAL 90-Y-ibritumomab tiuxetan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 1999-11 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005592
The ClinicalTrials.gov registry entry for NCT00005592 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which rituximab is the first listed.
NCT00005592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005592 about?
NCT00005592 is a clinical study titled "Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radiation to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of rituximab and ibritumomab tiuxetan in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
What is the current status of trial NCT00005592?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 1999-11. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00005592?
The interventions under investigation include: rituximab (BIOLOGICAL), indium In 111 ibritumomab tiuxetan (RADIATION), 90-Y-ibritumomab tiuxetan (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005592?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.